Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

One abstract reviewed results from Part A and Part C. 1 Part A was a 24-week study comparing dupilumab 300 mg vs placebo and Part C was a 28-week extended active treatment period for patients who ...

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, according to a ...

Meeting Coverage > ACG Dupilumab Helped Kids With Eosinophilic Esophagitis Achieve Needed Weight Gain — The drug also met primary endpoint of reducing peak esophageal intraepithelial eosinophil ...

A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.“Dupilumab, a human monoclonal antibody ...

The dupilumab group also saw an improvement in their hives symptoms, with an 8.5-point greater decrease versus the placebo group in their Urticaria Activity Score over 7 days (UAS7) for a mean ...

Compared with dupilumab, a significantly higher proportion of patients treated with upadacitinib achieved both EASI 90 and WP-NRS 0/1 at week 16. Among patients with moderate to severe atopic ...

Dupilumab-Associated Ocular Surface Disease in Patients With AD: Unravelling the Link Kate Johnson October 21, 2022 0 ...

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.